Antibody selection for immobilizing living bacteria.
We report a comparative study of the efficacy of immobilizing living bacteria by means of seven antibodies against bacterial surface antigens associated with Salmonella enterica Serovar Typhimurium. The targeted bacterial antigens were CFA/I fimbriae, flagella, lipopolysaccharides (LPS), and capsular F1 antigen. The best immobilization of S. Typhimurium was achieved with the antibody against CFA/I fimbriae. The immobilization of bacteria using antiflagellin showed significant enhancement if the flagella rotary motion was paralyzed. Of the four antibodies targeting LPS structures, only one, the antibody against the O-antigen polysaccharides, showed a relatively efficient bacterial immobilization. No bacterial immobilization was achieved using the antibody against F1 antigen, presumably because F1 protein can detach from the bacterial surface easily. The results suggest that an antibody for bacterial immunoimmobilization should target a surface antigen which extends out from the bacterial surface and is tightly attached to the bacterial cell wall. The microarrays of living S. Typhimurium cells immobilized in this manner remained viable and effective for at least 2 weeks in growth medium before a thick biofilm covered the whole surface.
Suo
Zhiyong
Z
Department of Physics, Montana State University, Bozeman, Montana 59717, USA.
Yang
Xinghong
X
Avci
Recep
R
Deliorman
Muhammedin
M
Rugheimer
Paul
P
Pascual
David W
DW
Idzerda
Yves
Y
D000907:Antibodies, Bacterial / Q000032:analysis*; D055910:Antibodies, Immobilized / Q000276:immunology / Q000378:metabolism*; D000942:Antigens, Bacterial / Q000276:immunology*; D046228:Microarray Analysis / Q000379:methods*; D018625:Microscopy, Atomic Force; D008855:Microscopy, Electron, Scanning; D012486:Salmonella typhimurium / Q000276:immunology / Q000302:isolation & purification*
D000907:Antibodies, Bacterial; D055910:Antibodies, Immobilized; D000942:Antigens, Bacterial
J Bacteriol. 1992 Mar;174(6):1916-22
1372317
Small. 2005 Apr;1(4):445-51
17193470
Science. 2002 Mar 1;295(5560):1702-5
11834780
Curr Opin Chem Biol. 2005 Oct;9(5):494-500
16125439
Anal Chem. 2004 May 15;76(10):2902-9
15144203
Vaccine. 2001 Jul 20;19(30):4175-84
11457543
Curr Opin Microbiol. 2003 Jun;6(3):206-12
12831895
Biochemistry. 2008 Oct 28;47(43):11332-9
18834143
Talanta. 2001 Dec 13;55(5):1029-38
18968453
Biotechnol Prog. 2004 Jul-Aug;20(4):1233-6
15296453
Int J Med Microbiol. 2000 Jul;290(3):279-83
10959730
Appl Microbiol Biotechnol. 2002 Nov;60(3):306-12
12436312
FEBS Lett. 1992 Feb 3;297(1-2):77-80
1551441
Anal Chem. 2004 Nov 1;76(21):6282-6
15516119
Ultramicroscopy. 2003 Oct-Nov;97(1-4):209-16
12801673
Biosens Bioelectron. 2004 Jun 15;19(11):1497-504
15093222
Biotechnology (N Y). 1995 Apr;13(4):366-72
9634778
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11059-64
9736689
J Bacteriol. 1998 Feb;180(4):1002-7
9473060
Infect Immun. 2006 Jun;74(6):3488-97
16714580
Anal Chem. 2008 Feb 15;80(4):1169-75
18217725
Langmuir. 2008 Apr 15;24(8):4161-7
18321142
Science. 1999 Jan 29;283(5402):661-3
9924019
J Bacteriol. 2001 Oct;183(19):5496-505
11544210
Langmuir. 2007 Jan 30;23(3):1365-74
17241060
FEMS Microbiol Lett. 2001 May 15;199(1):125-9
11356579
Biosens Bioelectron. 2005 Sep 15;21(3):500-7
16076440
Langmuir. 2009 Apr 21;25(8):4588-94
19260649
J Immunol. 2007 Jan 15;178(2):1059-67
17202369
Langmuir. 2006 Dec 19;22(26):11251-4
17154612
Clin Infect Dis. 1995 Oct;21 Suppl 2:S178-81
8845449